Current Affairs - Science - Discussion

The Democratic Republic of the Congo (DR Congo) launched the Tumaini clinical trial on October 23, 2026, to investigate whether existing and experimental vaccines can protect against the Bundibugyo strain of the Ebola virus. The first vaccination using Ervebo was administered in Bunia, located in the northeastern Ituri Province. The study is being conducted with support from the World Health Organisation (WHO). Ervebo is licensed to protect against Ebola disease caused by the Zaire species, but its effectiveness against the Bundibugyo strain remains uncertain. The trial will also evaluate vaccine candidates developed using adenoviral-vector and mRNA technologies to help improve protection against future outbreaks.